London, United Kingdom – Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today provides an update on current trading.

The company also reiterated guidance for its Branded business of revenue in the high-single digits, or 6% to 8% higher year-on-year, with a core operating margin around 25%. Its Generics business is ...

Analyst Christian Glennie from Stifel Nicolaus reiterated a Buy rating on Hikma Pharmaceuticals (HIK – Research Report) and keeping the ...

Hikma Pharmaceuticals reiterated its full-year outlook on Thursday on the back of strong trading across the business.

This might drive the stock higher in the near term. Hikma Pharmaceuticals ( LON:HIK ) First Half 2024 Results Key Financial Results Revenue: US$1.57b (up 10.0% from 1H... Shares of Hikma ...

After holding firm till around mid afternoon on Wednesday, European stocks pared gains and closed weak as investors assessed the ...

Global Alcoholic Hepatitis Treatment MarketAccording to a recent analysis by Future Market Insights (FMI), the global ...

Fintel reports that on October 30, 2024, EF Hutton initiated coverage of Carisma Therapeutics (NasdaqGM:CARM) with a Buy ...